Difficulty: Intermediate to Advanced
Prerequisites: Basic immunology (innate vs adaptive immunity, antibody structure, T cell and B cell function), introductory molecular biology, familiarity with protein engineering concepts.
Synthetic immunology sits at the crossroads of immunology and synthetic biology. It is about using engineered biological devices, from proteins to whole cells, to rationally control immune responses. The field matters because conventional immunosuppressants (corticosteroids, methotrexate) are blunt instruments with broad side effects; synthetic immunology aims to be precise. If you have a handle on how antibodies work, how T cells recognise targets, and why the immune system sometimes attacks the body's own tissue, you are ready for this material. If not, revisit basic adaptive immunity first.
Synthetic immunology engineers proteins (therapeutic antibodies, chimeric proteins, antibody derivatives, antibody mimetics) and immune cells (via surface engineering, gene therapy, adoptive immunotherapy) to treat autoimmune diseases, immunodeficiencies, and cancers. The goal is to manipulate the immune response with greater specificity than traditional drugs, though trade-offs in half-life, cost, immunogenicity, and off-target effects remain.
Synthetic immunology
An emerging field at the interface of immunology and synthetic biology that uses engineered biological devices (molecules and cells) to rationally modulate and manipulate immune responses.
Think of it as: designing custom-built biological tools to fine-tune the immune system, rather than relying on what nature provides.
Antibody-dependent cellular cytotoxicity (ADCC)
A mechanism in which innate immune cells (NK cells, macrophages) bearing Fc receptors (CD16, CD32, CD64) bind the Fc region of IgG1 or IgG3 antibodies coating a target cell. Crosslinking of these receptors activates the immune cell, which then kills the antibody-bound target.
In simple terms: the antibody flags the target, and an NK cell or macrophage reads the flag and destroys the cell.
Complement-dependent cytotoxicity (CDC)
The Fc region of IgG1, IgG3, or IgM binds complement factor C1q, which activates the complement cascade and assembles the membrane attack complex (MAC), leading to target cell lysis.
In simple terms: the antibody triggers a chain reaction of blood proteins that punch holes in the target cell's membrane.
Immunogenicity
The ability of a compound to provoke a humoral (antibody-mediated) or cell-mediated immune response in the host. In the context of therapeutics, this usually refers to the unwanted development of anti-drug antibodies against an engineered protein.
Think of it as: the patient's immune system treating the medicine itself as a foreign invader.
Biosimilars
Officially approved versions of an innovator biologic that contain the same genetic information as the original. Post-translational modifications may differ slightly.
In simple terms: the biologic equivalent of a generic drug, though not an exact copy because protein manufacturing introduces minor variation.
Chimeric antigen receptor (CAR)
A synthetic receptor engineered to redirect T cells (or NK cells) to a chosen target. It consists of single-chain variable fragments (scFvs) from an antibody fused to the transmembrane region and intracellular signalling domain of CD3-zeta. Third-generation CARs add co-stimulatory domains (CD28, 4-1BB, OX40) to boost potency.
In simple terms: a custom-built antenna bolted onto a T cell so it can recognise and attack a specific target, such as a tumour cell.
Cryopyrin-associated periodic syndrome (CAPS)
A family of autoinflammatory syndromes caused by mutations in NLRP3 (encoding cryopyrin, a component of the inflammasome). Mutations lead to overproduction of IL-1-beta and recurrent episodes of systemic inflammation.
Think of it as: a faulty thermostat on the inflammatory response, stuck in the "on" position.
Disease-modifying anti-rheumatic drugs (DMARDs)
A group of otherwise unrelated drugs defined by their use in rheumatoid arthritis (RA) to slow disease progression, rather than merely treating symptoms.
In simple terms: drugs that actually change the course of RA, not just painkillers.
An emerging field that uses engineered biological devices to rationally modulate immune responses
Covers two broad domains:
Molecular level: therapeutic antibodies, chimeric proteins, antibody derivatives, antibody mimetics
Cellular level: cell surface engineering, HSC gene therapy, adoptive immunotherapy
The aim is to manipulate the immune response using autologous (patient-derived) molecules and cells to target pathogenic proteins and cells without causing adverse effects
Also includes: synthetic vaccines, synthetic adjuvants, nanomaterials, antibody-recruiting molecules, and synthetic lymphoid tissue generated ex vivo
Natural killer (NK) cells: recognise and kill infected or tumour cells via NK receptors binding stress-related surface proteins, or via Fc receptors binding antibody-coated targets. Kill by two routes: cytotoxic granules (perforin and granzyme) or death-receptor ligand-induced apoptosis. Being harnessed for adoptive immunotherapies.
Dendritic cells (DCs): professional antigen-presenting cells. Sample molecules by endocytosis, process them, and present antigens via MHC class II. Interaction with lymphocytes in lymph nodes triggers adaptive immunity. Example therapeutic: sipuleucel-T (FDA-approved for prostate cancer, extended median survival by 4 months in Phase III).
Monocytes/macrophages: professional phagocytes that clear dying cells and microorganisms. Produce TNF and IL-1. Can be engineered, e.g. fed immunomodulatory microparticles to reduce inflammatory accumulation, or directed to help in bone regeneration.
Granulocytes: patrol the circulation, activated by pathogen-derived molecules binding pattern recognition receptors. Kill via phagocytosis, reactive oxygen species, degranulation, and DNA traps (NETs). Difficult to genetically manipulate due to short half-life and terminal differentiation.
B lymphocytes: recognise non-self via B cell receptors (BCRs). Endocytose, process, and present antigens via MHC class II (i.e. B cells are also antigen-presenting cells). T cell interaction via TCR-MHC class II drives B cell activation and differentiation into plasma cells (antibody factories) and memory B cells.
T lymphocytes:
CD8+ T cells: activated by non-self antigens on MHC class I (virus-infected cells, tumour cells). Release perforin, granzyme, and TNF. Also induce apoptosis via FasL-FAS interaction.
CD4+ T cells: activated by antigens on MHC class II from professional antigen-presenting cells. Release cytokines and modulate the immune response. Co-stimulation determines which cytokine set is produced.
Therapeutic applications: redirecting TCR specificity, engineering co-stimulation, preventing apoptosis, inducing inflammation.
First monoclonal antibodies engineered in the 1970s (Milstein and Kohler)
First approved: muromonab-CD3 (OKT3), 1986, for transplant rejection
Currently ~30 approved, 300+ in clinical trials
Four mechanisms of antibody action upon ligand binding:
Neutralisation: binding blocks ligand function
Targeted delivery: antibody carries toxic cargo to a specific cell
ADCC: NK cells or innate immune cells bind the Fc region and kill antibody-coated targets
CDC: Fc region activates complement cascade, causing apoptosis
Advantages: outstanding affinity, specificity, long plasma half-life
Limitations: large size prevents crossing cell membranes (restricted to extracellular targets), low tissue penetration, expensive (US $20,000 to $100,000 per patient per year)
Mouse monoclonal antibodies (-omab): raised entirely in non-human species. Example: muromonab-CD3 (OKT3). High immunogenicity; patients develop anti-drug antibodies.
Chimeric monoclonal antibodies (-ximab): mouse variable region linked to human constant region (~75% human). Examples: infliximab (anti-TNF, for RA and IBD), rituximab (anti-CD20, for B cell malignancies and autoimmune disease), basiliximab (anti-IL-2 receptor, for transplant rejection). Reduced anti-drug antibody development compared to fully mouse antibodies.
Humanized monoclonal antibodies (-zumab): only the mouse complementarity-determining region is kept, grafted onto a human scaffold (~95% human). Examples: alemtuzumab (anti-CD52, depletes lymphocytes via ADCC), natalizumab (anti-alpha-4 integrin, blocks lymphocyte motility, used in MS and Crohn's), omalizumab (anti-IgE, for allergic asthma).
Human monoclonal antibodies (-umab): fully human, generated via in vitro phage display, transgenic mice, or human hybridomas. Examples: adalimumab (anti-TNF, first FDA-approved human antibody), ipilimumab (anti-CTLA-4, checkpoint inhibitor for melanoma), nivolumab (anti-PD-1, checkpoint inhibitor for melanoma).
A major challenge in cancer immunotherapy: the immunosuppressive tumour microenvironment
Ipilimumab (anti-CTLA-4): CTLA-4 on T cells binds B7 on antigen-presenting cells, resulting in T cell anergy (a "brake" on activation). Ipilimumab blocks this interaction, releasing the brake. Median life expectancy of melanoma patients extended by 9 to 12 months.
Nivolumab (anti-PD-1): tumour cells express PD-L1, which binds PD-1 on T cells and induces T cell apoptosis. Nivolumab blocks PD-1, preventing tumour-induced T cell death. Increases life expectancy of melanoma patients considerably.
Combining ipilimumab and nivolumab in clinical trials has shown rapid tumour regression and promising survival, but with considerable adverse effects.
An IgG1 molecule consists of four polypeptide chains linked by disulphide bridges (~150 kDa total). The variable domains (V_H and V_L) bind antigens. The constant domains (C_L, C_H1, C_H2, C_H3) form the rigid backbone. The Fc region (C_H2 + C_H3) is responsible for effector functions (ADCC, CDC).
Mouse (-omab): 0% human sequence, highest immunogenicity
Chimeric (-ximab): ~75% human (human constant region, mouse variable region)
Humanized (-zumab): ~95% human (only the complementarity-determining region is mouse-derived)
Human (-umab): 100% human sequence, lowest immunogenicity
The suffix tells you the generation: -omab, -ximab, -zumab, -umab. The trend is from left to right: decreasing immunogenicity, increasing cost and complexity of production.
Infliximab (Remicade) and adalimumab (Humira) are among the highest-grossing drugs in history, used to treat RA and inflammatory bowel disease by neutralising TNF.
Checkpoint inhibitors (ipilimumab, nivolumab) have transformed melanoma treatment from a near-certain death sentence to a condition with meaningful survival extension.
"More human = always safer." Not quite. Even fully human antibodies can trigger anti-drug antibodies. Immunogenicity depends on more than just sequence homology; it also depends on the target and the mechanism.
"Therapeutic antibodies only suppress the immune system." Some antibodies activate the immune system. Checkpoint inhibitors (ipilimumab, nivolumab) release brakes on T cell activation to fight cancer.
"Chimeric and humanized are the same thing." They are not. Chimeric antibodies are ~75% human (entire mouse variable region retained). Humanized antibodies are ~95% human (only the small complementarity-determining region is mouse-derived).
"Specificity eliminates side effects." Even highly specific antibodies can produce significant on-target adverse effects, because their targets (e.g. TNF, CD20) play roles in normal immune defence. Patients on anti-TNF or anti-CD20 therapy frequently suffer from recurrent infections.
Know the four mechanisms of antibody action: neutralisation, targeted delivery, ADCC, CDC.
Be able to distinguish between mouse, chimeric, humanized, and human antibodies by suffix and % human sequence.
Understand how CTLA-4 and PD-1 function as immune checkpoints, and how ipilimumab and nivolumab reverse immunosuppression in tumours.
Expect questions on the trade-offs in Table 1 of the source article: each therapeutic approach has distinct advantages and disadvantages (half-life, cost, immunogenicity, tissue penetration).
The distinction between ADCC and CDC is commonly tested.
True or False: ADCC is triggered by the Fab region of an antibody. (False, it is triggered by the Fc region.)
Fill in the blank: A chimeric monoclonal antibody has the suffix ______. (-ximab)
True or False: Ipilimumab suppresses the immune response to treat autoimmune disease. (False, it activates the immune response by blocking the CTLA-4 checkpoint to treat cancer.)
Fill in the blank: The complement cascade is initiated when ______ binds to the Fc region of IgG1. (C1q)
True or False: Fully human antibodies carry zero risk of immunogenicity. (False, even fully human antibodies can trigger anti-drug antibodies.)
Q: Name the four mechanisms by which a therapeutic antibody can act upon binding its target.
A: (1) Neutralisation of ligand function, (2) targeted delivery of toxic cargo, (3) antibody-dependent cellular cytotoxicity (ADCC) via Fc receptor engagement on innate immune cells, (4) complement-dependent cytotoxicity (CDC) via C1q binding and the membrane attack complex.
Q: Explain how ipilimumab and nivolumab each promote anti-tumour immunity, and state their respective targets.
A: Ipilimumab targets CTLA-4. Normally, CTLA-4 on T cells binds B7 on antigen-presenting cells and causes T cell anergy. By blocking CTLA-4, ipilimumab removes this brake on T cell activation. Nivolumab targets PD-1. Tumour cells express PD-L1, which binds PD-1 on T cells and induces T cell apoptosis. Nivolumab blocks PD-1, preventing tumour-induced T cell death. Both result in enhanced T cell activity against the tumour.
Q: Why do patients treated with therapeutic antibodies against pro-inflammatory cytokines (e.g. anti-TNF) often suffer from recurrent infections?
A: The targeted cytokines (e.g. TNF) are not only drivers of chronic inflammation in autoimmune diseases but also essential mediators of normal immune defence against pathogens. Neutralising them reduces inflammation but simultaneously dampens the patient's ability to fight bacterial, viral, and fungal infections.
Q: Distinguish between a chimeric (-ximab) and a humanized (-zumab) monoclonal antibody in terms of structure and approximate percentage human sequence.
A: In a chimeric antibody, the entire mouse variable region (V_H and V_L) is retained and linked to the human constant region, yielding ~75% human sequence. In a humanized antibody, only the small complementarity-determining region (the antigen-binding loops) is mouse-derived, grafted onto a human antibody scaffold, yielding ~95% human sequence.
Q: What is the key structural difference between the Fab and Fc regions of an antibody, and what functional role does each serve?
A: The Fab region contains the variable domains (V_H and V_L) and is responsible for antigen binding (specificity). The Fc region contains the constant domains (C_H2 and C_H3) and mediates effector functions: it engages Fc receptors on innate immune cells (ADCC) and binds complement factor C1q (CDC). The Fc region also determines plasma half-life.
This material connects directly to basic antibody structure and immunoglobulin classes covered in introductory immunology. Understanding V_H, V_L, Fc, and Fab is prerequisite.
Checkpoint inhibitors (CTLA-4, PD-1) connect to T cell signalling and co-stimulation, often covered in a separate lecture on T cell biology.
The concept of immunogenicity ties into MHC presentation and adaptive immune recognition: the same mechanisms that protect against pathogens can also neutralise therapeutic proteins.
Synthetic immunology, therapeutic antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, ADCC, CDC, Fc receptor, complement cascade, C1q, membrane attack complex, immunogenicity, anti-drug antibodies, biosimilars, checkpoint inhibitors, CTLA-4, PD-1, PD-L1, ipilimumab, nivolumab, infliximab, rituximab, adalimumab, omalizumab, natalizumab, TNF blockers, immune checkpoint blockade, cancer immunotherapy, autoimmune disease treatment, transplant rejection, OKT3, muromonab